3
Announcements
Trials
Browse
Landscape
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Other neoplasm
1
Gastrointestinal
1
Conditions
Neoplasms
4
Breast Neoplasms
4
Myeloproliferative Disorders
3
Melanoma
3
Skin Neoplasms
2
Lung Neoplasms
2
Thrombosis
1
Pyruvate Kinase Deficiency of Red Cells
1
Precancerous Conditions
1
Pancreatic Neoplasms
1
Pancreatic Cyst
1
Neuroendocrine Tumors
1
Neoplasm, Residual
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Myelitis, Transverse
1
Myasthenia Gravis
1
Multiple Sclerosis
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphatic Metastasis
1
Locally Advanced Head and Neck Carcinoma
1
Leukemia, Myeloid, Acute
1
Hormone Receptor Positive Breast Cancer
1
Head and Neck Neoplasms
1
HER2-positive Breast Cancer
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Bevacizumab
26
Cetuximab
24
Fluorouracil
23
Leucovorin
22
Oxaliplatin
19
pembrolizumab
18
Specimen Handling
11
Irinotecan
10
Nivolumab
8
Magnetic Resonance Spectroscopy
8
atezolizumab
7
Biopsy
7
Pemetrexed
6
Panitumumab
6
Cisplatin
6
Carboplatin
6
trifluridine tipiracil drug combination
5
fludarabine
5
encorafenib
5
HMPL-013
5
Gemcitabine
5
Folfox protocol
5
Standard of Care
4
Immunoglobulin G
4
Disulfides
4
Cyclophosphamide
4
zanidatamab
3
regorafenib
3
fludarabine phosphate
3
dehydroftorafur
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colorectal Neoplasms
×
Blood Specimen Collection
×
30 days
×
Clear all
NCT07319104
2026-06-02
FECCO-BioBank
University Hospital, Montpellier
Not yet recruiting
1,000 enrolled